版本:
中国

BRIEF-VBL Therapeutics provides update on long-term survival in phase 2 trials of patients with multiple tumor types

June 19 Vascular Biogenics Ltd:

* VBL Therapeutics provides update on long-term survival in phase 2 trials of patients with multiple tumor types

* Vascular Biogenics- provided update on long term status,survival of patients from 3 completed phase 2 trials, which investigated co's vb-111

* Vascular Biogenics ltd - expect patient enrollment in our planned phase 3 oval study in ovarian cancer to begin in second half of 2017 for vb-111

* Vascular Biogenics Ltd - plan to launch a combination study of vb-111 with a checkpoint inhibitor in lung cancer by year-end 2017 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐